Therapeutic efficacy of vasoactive intestinal peptide in escherichia coli lipopolysaccharide-induced experimental periodontitis in rats

Journal of Periodontology

Volumn 80, Issue 10, 2009, Pages 1655-1664

  Gürkan, Ali ^a   Emingil, Gülnur ^a   Nizam, Nejat ^a   Doǧanavşargil, Başak ^a   Sezak, Murat ^a   Kütükçüler, Necil ^a   Atilla, Gül ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

Periodontitis; Rat; Therapy; Vasoactive intestinal peptide

Indexed keywords

IMMUNOLOGIC FACTOR; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE INTESTINAL POLYPEPTIDE;

ALVEOLAR BONE LOSS; ANIMAL; ARTICLE; BLOOD; COMPARATIVE STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; ESCHERICHIA COLI; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; PATHOLOGY; PERIODONTITIS; RANDOMIZATION; RAT; SPRAGUE DAWLEY RAT; TIME; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

ALVEOLAR BONE LOSS; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENDOTHELIUM, VASCULAR; ESCHERICHIA COLI; IMMUNOLOGIC FACTORS; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-10; INTERLEUKIN-18; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; MALE; OSTEOPROTEGERIN; PERIODONTITIS; RANDOM ALLOCATION; RANK LIGAND; RATS; RATS, SPRAGUE-DAWLEY; SODIUM CHLORIDE; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VASOACTIVE INTESTINAL PEPTIDE;

EID: 70349659726     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2009.090031     Document Type: Article

References (53)

1. Gonzalez-Rey E, Varela N, Chorny A, Delgado M. Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator. Curr Pharm Des 2007;13:1113-1139.
2. Delgado M, Pozo D, Ganea D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev 2004;56:249-290.
3. Gomariz RP, Martinez C, Abad C, Leceta J, Delgado M. Immunology of VIP: A review and therapeutical perspectives. Curr Pharm Des 2001;7:89-111.
4. Ganea D, Delgado M. Vasoactive intestinal peptide(VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity. Crit Rev Oral Biol Med 2002; 13:229-237.
5. Delgado M, Ganea D. Cutting edge: Is vasoactive intestinal peptide a type 2 cytokine? J Immunol 2001;166:2907-2912.
6. Delgado M, Abad C, Martinez C, et al. Vasoactive intestinal peptide in the immune system: Potential therapeutic role in inflammatory and autoimmune diseases. J Mol Med 2002;80:16-24.
7. Pozo D, Delgado M, Martínez M, et al. Immunobiology of vasoactive intestinal peptide (VIP). Immunol Today 2000;21:7-11.
8. Pozo D, Gonzalez-Rey E, Chorny A, Anderson P, Varela N, Delgado M. Tuning immune tolerance with vasoactive intestinal peptide: A new therapeutic approach for immune disorders. Peptides 2007;28:1833-1846. (Pubitemid 47361418)
9. Gonzalez-Rey E, Chorny A, Delgado M. Regulation of immune tolerance by anti-inflammatory neuropeptides. Nat Rev Immunol 2007;7:52-63.
10. De la Fuente M, Delgado M, Gomariz RP. VIP modulation of immune cell functions. Adv Neuroimmunol 1996;6:75-91.
11. Lundberg P, Lie A, Bjurholm A, et al. Vasoactive intestinal peptide regulates osteoclast activity via specific binding sites on both osteoclasts and osteoblasts. Bone 2000;27:803-810.
12. Mukohyama H, Ransjö M, Taniguchi H, Ohyama T, Lerner UH. The inhibitory effects of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide on osteoclast formation are associated with upregulation of osteoprotegerin and downregulation of RANKL and RANK. Biochem Biophys Res Commun 2000;271:158-163.
13. Pozo D, Delgado M. The many faces of VIP in neuroimmunology: A cytokine rather a neuropeptide? FASEB J 2004;18:1325-1334.
14. Linden GJ, Mullally BH, Burden DJ, et al. Changes in vasoactive intestinal peptide in gingival crevicular fluid in response to periodontal treatment. J Clin Periodontol 2002;29:484-489.
15. Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 2001;7:563-568.
16. Juarranz Y, Abad C, Martinez C, et al. Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res Ther 2005;7: R1034-1045.
17. Gonzalez-Rey E, Fernandez-Martin A, Chorny A, Delgado M. Vasoactive intestinal peptide induces CD4+,CD25+ T regulatory cells with therapeutic effect in collagen-induced arthritis. Arthritis Rheum 2006; 54:864-876.
18. Gonzalez-Rey E, Fernandez-Martin A, Chorny A, et al. Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: Down-regulation of inflammatory and autoimmune responses. Am J Pathol 2006;168:1179-1188.
19. Abad C, Martinez C, Juarranz MG, et al. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology 2003;124:961-971.
20. Groneberg DA, Rabe KF, Fischer A. Novel concepts of neuropeptide-based drug therapy: Vasoactive intestinal polypeptide and its receptors. Eur J Pharmacol 2006; 533:182-194.
21. Gonzalez-Rey E, Anderson P, Delgado M. Emerging roles of vasoactive intestinal peptide: A new approach for autoimmune therapy. Ann Rheum Dis 2007; 66(Suppl. 3):70-76.
22. Gonzalez-Rey E, Delgado M. Vasoactive intestinal peptide and regulatory T-cell induction: A new mechanism and therapeutic potential for immune homeostasis. Trends Mol Med 2007;13: 241-251.
23. Delgado M, Toscano MG, Benabdellah K, et al. In vivo delivery of lentiviral vectors expressing vasoactive intestinal peptide complementary DNA as gene therapy for collagen-induced arthritis. Arthritis Rheum 2008;58:1026-1037.
24. Kantarci A, Hastürk H, van Dyke TE. Host-mediated resolution of inflammation in periodontal diseases. Periodontol 2000 2006;40:144-163.
25. Salvi GE, Lang NP. Host response modulation in the management of periodontal diseases. J Clin Periodontol 2005;32(Suppl. 6):108-129.
26. Foster N, Cheetham J, Taylor JJ, Preshaw PM. VIP inhibits Porphyromonas gingivalis LPS-induced immune responses in human monocytes. J Dent Res 2005;84:999-1004.
27. Foster N, Lea SR, Preshaw PM, Taylor JJ. Pivotal advance: Vasoactive intestinal peptide inhibits upregulation of human monocyte TLR2 and TLR4 by LPS and differentiation of monocytes to macrophages. J Leukoc Biol 2007;81:893-903.
28. Foster N, Andreadou K, Jamieson L, Preshaw PM, Taylor JJ. VIP inhibits P. gingivalis LPS-induced IL-18 and IL-18BPa in monocytes. J Dent Res 2007;86:883-887.
29. Llavaneras A, Ramamurthy NS, Heikkilä P, et al. A combination of a chemically modified doxycycline and a bisphosphonate synergistically inhibits endotoxininduced periodontal breakdown in rats. J Periodontol 2001;72:1069-1077.
30. Llavaneras A, Golub LM, Rifkin BR, et al. CMT-8/ clodronate combination therapy synergistically inhibits alveolar bone loss in LPS-induced periodontitis. Ann N Y Acad Sci 1999;878:671-674.
31. Ramamurthy NS, Rifkin BR, Greenwald RA, et al. Inhibition of matrix metalloproteinase-mediated periodontal bone loss in rats: A comparison of 6 chemically modified tetracyclines. J Periodontol 2002; 73:726-734.
32. Ramamurthy NS, Xu JW, Bird J, et al. Inhibition of alveolar bone loss by matrix metalloproteinase inhibitors in experimental periodontal disease. J Periodontal Res 2002;37:1-7.
33. Buduneli E, Vardar-Sengül S, Buduneli N, Atilla G, Wahlgren J, Sorsa T. Matrix metalloproteinases, tissue inhibitor of matrix metalloproteinase-1, and laminin-5 gamma2 chain immunolocalization in gingival tissue of endotoxin-induced periodontitis in rats: Effects of low-dose doxycycline and alendronate. J Periodontol 2007;78:127-134.
34. Graves DT, Fine D, Teng YT, Van Dyke TE, Hajishengallis G. The use of rodent models to investigate hostbacteria interactions related to periodontal diseases. J Clin Periodontol 2008;35:89-105.
35. Zhang D, Chen L, Li S, Gu Z, Yan J. Lipopolysaccharide (LPS) of Porphyromonas gingivalis induces IL-1beta, TNF-alpha and IL-6 production by THP-1 cells in a way different from that of Escherichia coli LPS. Innate Immun 2008;14:99-107.
36. Martin M, Katz J, Vogel SN, Michalek SM. Differential induction of endotoxin tolerance by lipopolysaccharides derived from Porphyromonas gingivalis and Escherichia coli. J Immunol 2001;167(9):5278-5285.
37. Liu R, Desta T, Raptis M, Darveau RP, Graves DTP. P. gingivalis and E. coli lipopolysaccharides exhibit different systemic but similar local induction of inflammatory markers. J Periodontol 2008;79:1241-1247.
38. Park CH, Abramson ZR, Taba M Jr., et al. Threedimensional micro-computed tomographic imaging of alveolar bone in experimental bone loss or repair. J Periodontol 2007;78:273-281.
39. Rogers JE, Li F, Coatney DD, et al. Actinobacillus actinomycetemcomitans lipopolysaccharide-mediated experimental bone loss model for aggressive periodontitis. J Periodontol 2007;78:550-558.
40. Abad C, Gomariz RP, Waschek JA. Neuropeptide mimetics and antagonists in the treatment of inflammatory disease: Focus on VIP and PACAP. Curr Top Med Chem 2006;6:151-163.
41. Bartold PM, Marshall RI, Haynes DR. Periodontitis and rheumatoid arthritis: A review. J Periodontol 2005; 76:2066-2074.
42. Zauli G, Corallini F, Bossi F, et al. Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood 2007;110:536-543.
43. Rameshwar P, Gascon P, Oh HS, Denny TN, Zhu G, Ganea D. Vasoactive intestinal peptide (VIP) inhibits the proliferation of bone marrow progenitors through the VPAC1 receptor. Exp Hematol 2002;30:1001-1009.
44. Hernanz A, Medina S, de Miguel E, Martín-Mola E. Effect of calcitonin gene-related peptide, neuropeptide Y, substance P, and vasoactive intestinal peptide on interleukin-1beta, interleukin-6 and tumor necrosis factor-alpha production by peripheral whole blood cells from rheumatoid arthritis and osteoarthritis patients. Regul Pept 2003;115:19-24.
45. Gó rska R, Gregorek H, Kowalski J, Laskus-Perendyk A, Syczewska M, Madaliń ski K. Relationship between clinical parameters and cytokine profiles in inflamed gingival tissue and serum samples from patients with chronic periodontitis. J Clin Periodontol 2003;30: 1046-1052.
46. Yamazaki K, Honda T, Oda T, et al. Effect of periodontal treatment on the C-reactive protein and proinflammatory cytokine levels in Japanese periodontitis patients. J Periodontal Res 2005;40:53-58.
47. Bostanci N, Ilgenli T, Emingil G, et al. Gingival crevicular fluid levels of RANKL and OPG in periodontal diseases: Implications of their relative ratio. J Clin Periodontol 2007;34:370-376.
48. Bostanci N, Ilgenli T, Emingil G, et al. Differential expression of receptor activator of nuclear factor- kappaB ligand and osteoprotegerin mRNA in periodontal diseases. J Periodontal Res 2007;42: 287-293.
49. Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W, Osdoby P. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 2001;276:20659-20672.
50. Kobayashi-Sakamoto M, Hirose K, Isogai E, Chiba I. NF-kappaB-dependent induction of osteoprotegerin by Porphyromonas gingivalis in endothelial cells. Biochem Biophys Res Commun 2004;315: 107-112.
51. Brandi ML, Collin-Osdoby P. Vascular biology and the skeleton. J Bone Miner Res 2006;21:183-192.
52. Crotti T, Smith MD, Hirsch R, et al. Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. J Periodontal Res 2003;38:380-387.
53. Lerner UH, Persson E. Osteotropic effects by the neuropeptides calcitonin gene-related peptide, substance P and vasoactive intestinal peptide. J Musculoskelet Neuronal Interact 2008;8:154-165.